IDEAYA Biosciences, Inc. (IDYA) Q4 2022 Earnings Results

IDEAYA Biosciences I Beats on EPS, Stock Up 6.17%

IDEAYA Biosciences I's earnings report showed a smaller-than-expected loss per share, which pleased investors and led to a 6.17% increase in stock price. However, the lack of revenue data and guidance leaves some uncertainty about the company's financial health moving forward. Investors may be optimistic about the company's focus on its pipeline despite these gaps in information.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.50	N/A	+11.50%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Management expressed satisfaction with the EPS results despite not providing revenue figures. They emphasized their commitment to pipeline development.

We are pleased with our EPS performance this quarter.

Our focus remains on advancing our pipeline.

IDEAYA Biosciences I Beats on EPS, Stock Up 6.17%

Key numbers

Management commentary

IDEAYA Biosciences, Inc.

More earnings this week

IDEAYA Biosciences I Beats on EPS, Stock Up 6.17%

Key numbers

Management commentary